Clinical trial · Observational
Monitoring MRI Changes Before and During Radiotherapy Treatment of Brain Tumors
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Low inclusion rate; Change of position of principal investigator.
Summary
Brief summary (as posted)
This study aims to evaluate anatomical and functional changes during RT for patients receiving fractionated RT for brain tumors. Anatomical changes during RT will be registered and analyzed and if needed the radiotherapy plan will be modified for the individual patient. This means that the "to be irradiated volume" will be modified according to the shape changes of the tumor. The functional MRI sequences will be used to evaluate what parameters, and at which time point, are important for radiotherapy outcome.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patient brain tumor treated with fractionated radiotherapy
- interventionNames
- Radiation: Radiotherapy
Primary outcomes (2)
- measure
- MRI parameters in the target volume
- timeFrame
- through study completion, an average of 3 years
- description
- functional MRI parameters (permeability, perfusion and diffusion) in the target volume before and during fractional radiotherapy treatment
- measure
- anatomical variations in position, shape and size in the target volume
- timeFrame
- through study completion, an average of 3 years
- description
- The difference is position shape and size in the target volume before and during fractional radiotherapy treatment. In case there is no macroscopic extension beyond the clinical target volume the new target volumes (gross target volume (GTV) and clinical target volume (CTV).) will also (but later) be delineated for analysis of volume changes, center of mass changes and distance measurements between the delineation on planning MRI versus repeated MRI.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary brain tumor (WHO IV, GBM); treated with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy. * Brain metastasis (from a solid extracranial tumor) eligible for treatment with fractionated radiotherapy with or without preceding surgery. Systemic treatment is allowed before and during radiotherapy. Also, postoperative patients with a macroscopic residual tumor lesion can be included (the diagnosis of residual diseases is defined by the treating neurosurgeon or on the MRI executed within 24 hours after the surgery, the diagnosis of residual macroscopic disease should always be confirmed during the neuro-oncology multidisciplinary meeting). Exclusion Criteria: * Patients receiving Whole Brain RT (WBRT) * Patient with a poor kidney function (GFR \< 30 mL/min; CKD 4 and 5; patients on dialysis and patients with acute kidney insufficiency) * None, doubtful or very small (\<5 mm in its largest dimension) contrast enhancing lesion * Patients with a contraindication for MRI
References
Publications (0)
Data not yet available